- Clinical Trials
- March 2020
- 421 Pages
Global
From €2378EUR$2,500USD£2,024GBP
- Report
- July 2020
- 81 Pages
Global
From €4281EUR$4,500USD£3,644GBP
- Report
- August 2023
- 99 Pages
Global
From €3500EUR$3,941USD£3,084GBP
- Report
- February 2022
- 235 Pages
Global
From €3531EUR$3,712USD£3,006GBP
- Report
- March 2022
- 157 Pages
Global
From €3531EUR$3,712USD£3,006GBP
- Report
- September 2021
- 210 Pages
Global
From €3531EUR$3,712USD£3,006GBP
- Report
- February 2024
- 180 Pages
Global
From €5231EUR$5,499USD£4,453GBP
Macular Edema is a condition in which fluid accumulates in the macula, the central part of the retina responsible for sharp, central vision. It is a common complication of diabetes, and can also be caused by other diseases or conditions such as uveitis, retinal vein occlusion, and retinopathy of prematurity. Treatment options for macular edema include laser photocoagulation, intravitreal injections, and vitrectomy.
Optical treatments for macular edema include laser photocoagulation, which uses a laser to reduce the amount of fluid in the macula. Intravitreal injections are also used to reduce fluid accumulation, and vitrectomy is a surgical procedure that removes the vitreous gel from the eye and replaces it with a gas bubble.
Companies in the macular edema market include Regeneron Pharmaceuticals, Allergan, Novartis, Roche, and Bayer. Show Less Read more